R&D Platform
Enzon has a portfolio of four marketed products, ONCASPAR®, DEPOCYT®, ABELCET® and ADAGEN®. The Company's drug developmentprograms utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, ONCASPAR and ADAGEN, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base.
